Jump Financial LLC Sells 28,022 Shares of Immunocore Holdings plc (NASDAQ:IMCR)

Jump Financial LLC reduced its position in Immunocore Holdings plc (NASDAQ:IMCR) by 46.2% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 32,600 shares of the company’s stock after selling 28,022 shares during the quarter. Jump Financial LLC’s holdings in Immunocore were worth $962,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. boosted its position in shares of Immunocore by 12.9% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,393 shares of the company’s stock valued at $248,000 after acquiring an additional 960 shares during the period. NEOS Investment Management LLC increased its stake in Immunocore by 10.9% in the fourth quarter. NEOS Investment Management LLC now owns 11,194 shares of the company’s stock valued at $330,000 after acquiring an additional 1,102 shares during the last quarter. XTX Topco Ltd boosted its stake in shares of Immunocore by 22.2% in the 4th quarter. XTX Topco Ltd now owns 18,896 shares of the company’s stock valued at $557,000 after purchasing an additional 3,437 shares in the last quarter. Barclays PLC grew its position in Immunocore by 2,044.0% during the 4th quarter. Barclays PLC now owns 20,625 shares of the company’s stock worth $608,000 after acquiring an additional 19,663 shares during the last quarter. Finally, Assetmark Inc. increased its position in shares of Immunocore by 5.3% in the fourth quarter. Assetmark Inc. now owns 32,171 shares of the company’s stock valued at $949,000 after acquiring an additional 1,616 shares during the period. 84.50% of the stock is currently owned by institutional investors.

Immunocore Trading Up 3.5 %

IMCR stock opened at $29.41 on Tuesday. Immunocore Holdings plc has a fifty-two week low of $23.15 and a fifty-two week high of $62.74. The firm has a market cap of $1.47 billion, a PE ratio of -30.96 and a beta of 0.75. The firm has a fifty day moving average price of $28.74 and a 200 day moving average price of $30.36. The company has a debt-to-equity ratio of 1.03, a quick ratio of 3.76 and a current ratio of 3.78.

Insider Buying and Selling

In related news, Director Bros. Advisors Lp Baker bought 807,338 shares of the company’s stock in a transaction on Monday, March 17th. The shares were acquired at an average cost of $29.72 per share, for a total transaction of $23,994,085.36. Following the purchase, the director now directly owns 2,144,060 shares of the company’s stock, valued at approximately $63,721,463.20. The trade was a 60.40 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 10.40% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on IMCR. JPMorgan Chase & Co. decreased their price target on shares of Immunocore from $54.00 to $50.00 and set an “overweight” rating for the company in a research note on Monday, April 14th. Morgan Stanley reiterated an “equal weight” rating and set a $35.00 target price on shares of Immunocore in a research note on Friday, March 7th. Needham & Company LLC reissued a “buy” rating and set a $71.00 price objective on shares of Immunocore in a report on Thursday, April 10th. Mizuho dropped their target price on Immunocore from $38.00 to $33.00 and set a “neutral” rating on the stock in a research report on Monday, April 7th. Finally, HC Wainwright reiterated a “buy” rating and set a $100.00 target price on shares of Immunocore in a research report on Wednesday, March 12th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $63.73.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.